EU Member States Meet to Discuss Drug Shortages During COVID-19
The EU Executive Steering Group on Shortages of Medicines Caused by Major Events met on May 13, 2020 to discuss measures the European Union is taking to ensure the availability of medicines during the COVID-19 pandemic.
The European Medicines Agency (EMA) announced on May 15, 2020 that the EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a virtual meeting on May 13, 2020 to discuss actions taken by authorities in the European Union to ensure the availability of medicines in Europe during the COVID-19 pandemic. The meeting included heads of national competent authorities (NCAs) of the EU Member States.
The continued roll out of the i-SPOC system was discussed during the meeting. The system allows industry to notify EMA and EU Member States of current or anticipated shortages of drugs crucial to the pandemic. Improvement of the supply of drugs used in intensive care units (ICUs) was discussed due to reported shortages of ICU medicines. Participants discussed the development of joint principles for assessing demand at the national level. The sharing of demand data by the NCAs was determined to be useful to ensure supply of ICU medicines. Information on models currently in use by some Member States was shared, and ways of improving forecasting capacities and data modeling best practices were discussed.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
